CNS Pharmaceuticals Inc.
13F holders, Q2 2024 (June 30)10holders
$1.58avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding CNS Pharmaceuticals Inc. in their 13F filings. The largest holders were Anson Funds Management LP ($223K), UBS Group AG ($4K) and Tower Research Capital LLC (TRC) ($182).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H300
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 11 | $228K |
| Exits | 0 | $0 |
Ownership 10 holders
| Anson Funds Management LP | 0.03% | New | 141,398 | $223K |
| UBS Group AG | 0.00% | New | 2,629 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 115 | $182 |
| Wells Fargo & Company | 0.00% | New | 4 | $6 |
| Morgan Stanley | 0.00% | New | 2 | $3 |
| Global Retirement Partners, LLC | 0.00% | New | 2 | $3 |
| Bank of America Corp. | 0.00% | New | 1 | $2 |
| FMR LLC | 0.00% | New | 1 | $2 |
| Plante Moran Financial Advisors, LLC | 0.00% | New | 1 | $2 |
| Parallel Advisors, LLC | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is CNS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.